Accurate Patient-Specific Machine Learning Models of Glioblastoma Invasion Using Transfer Learning

References

1. 1.↵
   2. Sarkaria JN,
   3. Hu LS,
   4. Parney IF, et al

   . Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro Oncol 2018;20:184–91 doi:10.1093/neuonc/nox175 pmid:29016900

   CrossRefPubMed
2. 2.↵
   2. Barajas RF Jr.,
   3. Hodgson JG,
   4. Chang JS, et al

   . Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology 2010;254:564–76 doi:10.1148/radiol.09090663 pmid:20093527

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Hu LS,
   3. Ning S,
   4. Eschbacher JM, et al

   . Multi-parametric MRI and texture analysis to visualize spatial histologic heterogeneity and tumor extent in glioblastoma. PLoS One 2015;10:e0141506 doi:10.1371/journal.pone.0141506 pmid:26599106

   CrossRefPubMed
4. 4.↵
   2. Baldock AL,
   3. Ahn S,
   4. Rockne R1, et al

   . Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. PLoS One 2014;9:e99057 doi:10.1371/journal.pone.0099057 pmid:25350742

   CrossRefPubMed
5. 5.↵
   2. Price SJ,
   3. Jena R,
   4. Burnet NG, et al

   . Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol 2006;27:1969–74 pmid:17032877

   Abstract/FREE Full Text
6. 6.↵
   2. Hu LS,
   3. Ning S,
   4. Eschbacher JM, et al

   . Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol 2017;19:128–37 doi:10.1093/neuonc/now135 pmid:27502248

   CrossRefPubMed
7. 7.↵
   2. Corwin D,
   3. Holdsworth C,
   4. Rockne RC, et al

   . Toward patient-specific, biologically optimized radiation therapy plans for the treatment of glioblastoma. PLoS One 2013;8:e79115 doi:10.1371/journal.pone.0079115 pmid:24265748

   CrossRefPubMed
8. 8.↵
   2. Pafundi DH,
   3. Laack NN,
   4. Youland RS, et al

   . Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 2013;15:1058–67 doi:10.1093/neuonc/not002 pmid:23460322

   CrossRefPubMed
9. 9.↵
   2. Ellingson BM,
   3. Malkin MG,
   4. Rand SD, et al

   . Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 2010;31:538–48 doi:10.1002/jmri.22068 pmid:20187195

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Mohsen LA,
    3. Shi V,
    4. Jena R., et al

    . Diffusion tensor invasive phenotypes can predict progression-free survival in glioblastomas. Br J Neurosurg 2013;27:436–41 doi:10.3109/02688697.2013.771136 pmid:23445331

    CrossRefPubMed
11. 11.↵
    2. Stadlbauer A,
    3. Ganslandt O,
    4. Buslei R., et al

    . Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 2006;240:803–10 doi:10.1148/radiol.2403050937 pmid:16926329

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Hu LS,
    3. Eschbacher JM,
    4. Dueck AC, et al

    . Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 2012;33:69–76 doi:10.3174/ajnr.A2743 pmid:22095961

    Abstract/FREE Full Text
13. 13.↵
    2. Hu LS,
    3. Baxter LC,
    4. Smith KA, et al

    . Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552–58 doi:10.3174/ajnr.A1377 pmid:19056837

    Abstract/FREE Full Text
14. 14.↵
    2. Hu LS,
    3. Eschbacher JM,
    4. Heiserman JE, et al

    . Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol 2012;14:919–30 doi:10.1093/neuonc/nos112 pmid:22561797

    CrossRefPubMed
15. 15.↵
    2. LaViolette PS,
    3. Mickevicius NJ,
    4. Cochran EJ, et al

    . Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro Oncol 2014;16:1599–1606 doi:10.1093/neuonc/nou142 pmid:25059209

    CrossRefPubMed
16. 16.↵
    2. Chang PD,
    3. Malone HR,
    4. Bowden SG, et al

    . A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies. AJNR Am J Neuroradiol 2017;38:890–98 doi:10.3174/ajnr.A5112 pmid:28255030

    Abstract/FREE Full Text
17. 17.↵
    2. Eidel O,
    3. Neumann JO,
    4. Burth S, et al

    . Automatic analysis of cellularity in glioblastoma and correlation with ADC using trajectory analysis and automatic nuclei counting. PLoS One 2016;11:e0160250 doi:10.1371/journal.pone.0160250 pmid:27467557

    CrossRefPubMed
18. 18.↵
    2. Barajas RF Jr.,
    3. Phillips JJ,
    4. Parvataneni R, et al

    . Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging. Neuro Oncol 2012;14:942–54 doi:10.1093/neuonc/nos128 pmid:22711606

    CrossRefPubMed
19. 19.↵
    2. Sadeghi N,
    3. D'Haene N,
    4. Decaestecker C, et al

    . Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 2008;29:476–82 doi:10.3174/ajnr.A0851 pmid:18079184

    Abstract/FREE Full Text
20. 20.↵
    2. Price SJ,
    3. Green HA,
    4. Dean AF, et al

    . Correlation of MR relative cerebral blood volume measurements with cellular density and proliferation in high-grade gliomas: an image-guided biopsy study. AJNR Am J Neuroradiol 2011;32:501–06 doi:10.3174/ajnr.A2312 pmid:21163880

    Abstract/FREE Full Text
21. 21.↵
    2. Beppu T,
    3. Inoue T,
    4. Shibata Y, et al

    . Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas. Surg Neurol 2005;63:56–61; discussion 61 doi:10.1016/j.surneu.2004.02.034 pmid:15639528

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Durst CR,
    3. Raghavan P,
    4. Shaffrey ME, et al

    . Multimodal MR imaging model to predict tumor infiltration in patients with gliomas. Neuroradiology 2014;56:107–15 doi:10.1007/s00234-013-1308-9 pmid:24337609

    CrossRefPubMed
23. 23.↵
    2. Semmineh NB,
    3. Xu J,
    4. Skinner JT, et al

    . Assessing tumor cytoarchitecture using multiecho DSC-MRI derived measures of the transverse relaxivity at tracer equilibrium (TRATE). Magn Reson Med 2015;74:772–84 doi:10.1002/mrm.25435 pmid:25227668

    CrossRefPubMed
24. 24.↵
    2. Lowekamp BC,
    3. Chen DT,
    4. Ibáñez L, et al

    . The design of simple eITK. Front Neuroinform 2013;7:45 doi:10.3389/fninf.2013.00045

    CrossRef
25. 25.↵
    2. Sethian JA

    . Level Set Methods and Fast Marching Methods: Evolving Interfaces in Computational Geometry, Fluid Mechanics, Computer Vision, and Materials Science. New York: Cambridge University Press, 1999
26. 26.↵
    2. Tustison NJ,
    3. Avants BB,
    4. Cook PA, et al

    . N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 2010;29:1310–20 doi:10.1109/TMI.2010.2046908 pmid:20378467

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Mitchell JR,
    3. Jones C,
    4. Karlik SJ, et al

    . MR multispectral analysis of multiple sclerosis lesions. J Magn Reson Imaging 1997; 7:499–511 doi:10.1002/jmri.1880070309 pmid:9170034

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Hu LS,
    3. Kelm Z,
    4. Korfiatis P, et al

    . Impact of software modeling on the accuracy of perfusion MRI in glioma. AJNR Am J Neuroradiol 2015;36:2242–49 doi:10.3174/ajnr.A4451 pmid:26359151

    Abstract/FREE Full Text
29. 29.↵
    2. Boxerman JL,
    3. Schmainda KM,
    4. Weisskoff RM

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67 pmid:16611779

    Abstract/FREE Full Text
30. 30.↵
    2. Benjamini Y,
    3. Hochberg Y

    . Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 1995;57:289–300 doi:10.1111/j.2517-6161.1995.tb02031.x

    CrossRef
31. 31.↵
    2. Weiss K,
    3. Khoshgoftaar TM,
    4. Wang D

    . A survey of transfer learning. J Big Data 2016;3:9
32. 32.↵
    2. Pan SJ,
    3. Yang Q

    . A survey on transfer learning. IEEE Trans Knowl Data Eng 2009;22:1345–59
33. 33.↵
    2. Zou N,
    3. Baydogan M,
    4. Zhu Y, et al

    . A transfer learning approach for predictive modeling of degenerate biological systems. Technometrics 2015;57:362–73 doi:10.1080/00401706.2015.1044117 pmid:27330227

    CrossRefPubMed
34. 34.↵
    2. Brown R,
    3. Zlatescu M,
    4. Sijben A, et al

    . The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 2008;14:2357–62 doi:10.1158/1078-0432.CCR-07-1964 pmid:18413825

    Abstract/FREE Full Text
35. 35.↵
    2. Dalrymple SJ,
    3. Parisi JE,
    4. Roche PC, et al

    . Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery 1994;35:1036–44; discussion 1044–55 doi:10.1227/00006123-199412000-00004 pmid:7885547

    CrossRefPubMedWeb of Science